Children’s Hospital (Philadelphia)

PI: Smita Bhatia, MD, MPH

The primary goal of this study is to determine whether patients assigned to receive DRZ have less damage to their heart compared to those who didn't receive it. We will also evaluate whether DRZ's cardioprotective effect changes by anthracycline dose, chest radiation, and other factors such as age, and gender. We will also look at survival rates between patients treated with and without dexrazoxane.

National Heart, Lung, and Blood Institute/NIH/DHHS

PI: Burel Goodin, PhD

If our hypotheses are confirmed, we will identify: 1) insomnia as a major driver of pain in the laboratory and in everyday life among PLWH, and 2) inflammation as an important insomnia-related mediator of pain in PLWH. This research could help confirm insomnia as a therapeutic target for the suppression of pain and inflammation in PLWH. Possible treatments may include cognitive-behavioral therapy for insomnia and anti-inflammatories.

National Institute of Nursing Research/NIH/DHHS 

PI: Macy Stockdill, pre-doctoral student
Mentor: Marie Bakitas, DNSc, NP-C, FAAN

The purpose of this research study is to identify symptom pattern trajectories in a diverse sample of heart failure patients living in the Southeast.

National Cancer Institute

Co-I: Ellen M. Lavoie Smith, PhD, MSN, RN, AOCN, FAAN

The test a personalized exergame intervention to improve pain and fatigue following chemotherapy/radiation treatment for head and neck cancer.

Disarm Therapeutics

Co-I: Ellen M. Lavoie Smith, PhD, MSN, RN, AOCN, FAAN

To validate a biomarker of peripheral nerve axon damage following neurotoxic chemotherapy in patients receiving paclitaxel or vincristine for breast cancer and lymphoma